Parvovirus Infection – Contemporary Issues in Epidemiology and Clinical Medicine
https://doi.org/10.31631/2073-3046-2015-14-4-29-35
Abstract
Parvovirus infection (PVI) is an important but little-known problem in the Russian Federation. Its clinical manifestations are characterized by different clinical entities that require differential diagnosis, as with other viral infections, as well as non-communicable diseases and epidemiological significance of PVI determined the prevalence of the development of epidemic outbreaks, mainly in organized groups. Medical and social - with teratogenic virus, as well as the possibility of its transmission at gematransfuziyah. The main risk groups - pregnant women, patients hematological profile. In the absence of recording and reporting the incidence of people is impossible to establish the scale of the spread of parvovirus infection. Crucial in this respect are laboratory studies that reveal the prevalence of its laboratory markers.
About the Authors
O. N. Nikishov
Federal State Military Educational Institution of Additional Professional Education «Military Medical Academy named S.M. Kirov» Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
A. A. Kuzin
Federal State Military Educational Institution of Additional Professional Education «Military Medical Academy named S.M. Kirov» Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
A. Yu. Antipova
Federal Budgetary Institution of Science «Pasteur Research Institute of Epidemiology & Microbiology»
Russian Federation
Russian Federation
I. N. Lavrent’eva
Federal Budgetary Institution of Science «Pasteur Research Institute of Epidemiology & Microbiology»
Russian Federation
Russian Federation
References
1. Antipovа A. Y., Lavrentievа I.N., Bichurina M.A., Lyalina L.V., Kutueva F.R. et al. The spread of parvovirus infection in the Northwestern federal district of Russia. J. Infectology. 2011; 3 (4): 44 – 48 (in Russian).
2. Antipovа A.Y. The value of laboratory diagnosis of rubella and parvovirus infection in the elimination of rubella: Doctorate of biol. sci. diss. Science. Saint Petersburg: 2013: 23 (in Russian).
3. Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lanset. 1975; 1: 137 – 142.
4. International Committee on Taxonomy of Viruses. Available at: http://ictvonline.org/virusTaxonomy.asp
5. Mori J., Beattie P., Melton D.W., Cohen B.J,Clewley J.P. Structure and mapping of the DNA of human parvovirus B19. J. Gen. Virol. 1987; 68: 2797 – 2806.
6. Young N.S., Brown K.E. Mechanisms of disease: Parvovirus. N. Engl. J. Med. 2004; 350 (6): 586 – 597.
7. Alimbarova L.M. Parvovirus (Parvoviridae). Proc. Manual of Medical Virology, ed. Lvov DK, Moscow 2008: 276 – 284 (in Russian).
8. Amand St., Astell J., Astell C.R. Indentification and sharacterization of a family of 11-kDa proteins encoded by hyman parvovirus B19. Virology. 1993; 192: 121 – 131.
9. Lavrentiev I.N., Antipovа A.Yu. Human parvovirus B19: characterization and diagnosis of pathogen infections caused by them. Infection and Immunity. 2012; 4: 314 – 316 (in Russian).
10. Baylis S.A. Standardization of nucleic acid amplification technique (NAT) -based assays for different genotypes of parvovirus B19: a meeting summary. Vox Sanguinis. 2008; 94: 74 – 80.
11. Corcoran A., Doyle S. Advances in the biology, diagnosis and host-pathogen interactionsof parvovirus B19, J. Med. Microbiol. 2004; 53: 459 – 475.
12. Anderson L.J., Gillespie S.M., Torok T.J., Hurwitz E.S., Tsou C. J., Gary G.W.. Risk of infection following exposures to human parvovirus B19. Behring Inst. Mitt. 1990; 85: 60 – 63.
13. Blumel J., Eis-Hubinger A.M., Stuhler A., Bonsch C., Gessner M., Lower J. Characterization of Parvovirus B19 genotypes 2 in KU812Ep6 cells. J.Virol. 2005; 79 (22): 14197 – 14206.
14. Lou S., Xu B., Xuang Q., Zhi N., Cheng F., Wong S., Brown K. Molecular sharacterization of the newly identified human parvovirus 4 in the family Parvoviridae. Virology. 2012, 422: 59 – 69.
15. Livada A.I. Parvovirus B19 infection. Pediatrician online. 2012 (in Russian).
16. Allander N. Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloing of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl Acad. Sci. U.S.A. 2005; 102: 12891 – 12896.
17. Smelik J.A., Parvovirus (B19) infection in children at the present stage (review). Bulletin of KSMA them. I.K. Ahunbaeva. 2011; (4): 20 – 24 (in Russian).
18. International Classification of Diseases (ICD-10). Available at: http://www.cdc.gov/ (in Russian).
19. Tikhonovа N.T. Evaluation of the spread of parvovirus infection in Moscow. Information Letter of the Health Committee of Moscow. Moscow; 2004; (11): 12 (in Russian).
20. Lushnova I.V. Parvovirus B19 infection. Pediatrician. 2010; 1: 115 – 118 (in Russian).
21. Broliden K., Tolfvenstam T., Norbeck O. Clinical aspects of parvovirus B19 infection. J. Intern. Med. 2006; 260: 285 – 304.
22. Gustafsson I., Evolution of Parvovirus B19 infection in children with malignant or hematological disorders. Clin. Infect. Dis. 2010; 50 (10): 1426 – 1427.
23. Lavrentieva I.N., Antipova A.Yu., Semenov, A.N., Bichurina M.A. Genotyping of isolates pavrvovirusa B19, circulating in the Northwest region of the Russian Federation. Zh. microbiology. 2013; 6: 36 – 43 (in Russian).
24. Wong A., Tan K.H., Tee C.S., Yeo G.S.H. Seroprevalence of Cytomegalovirus, Toxoplasma and parvovirus in pregnancy. Signapore Med J. 2000; 1 (4): 151 – 155 (in Russian).
25. Vasiliev V.V., Murin E.A., Sidorenko S.V, Mukomolova A.L. et al. Parvovirus (V19V) infection in pregnant women and young children. Journal infektologii. 2011; 3 (4): 26 – 33.
26. Centres for Disease Control. Current trends risks associated with human Parvovirus B19 infection. MMWR Morb Mortal WKLY Rep. 1989; 38 (6): 81 – 88, 93 – 97. Available at: httр://www.cdc.gov/mmwr/preview/mmwrhtm/00001348.htm.
27. Jones M.S. New DNA viruses identified in patiens with acute viral infection syndrome, J. Virol. 2005; 79: 8230 – 8236.
28. Savaresi I. Atypical manifestations of congenital parvovirus B19 infection. Eur. J. Pediatr. 2008; 167 (12): 1463 – 1466.
29. Bernuau J., Durand F., Valla D. Parvovirus B19 infection and ful-minant hepatitis. Lancet. 1999; 353 (9154): 754 – 755.
30. Abe K., Kiuchi T., Tanaka K. Edamoto Y, Aiba N, Sata T.. Characterization of erythrovirus B19 genomes isolated in liver tissues from patients with fulminant hepatitis and biliary atresia who underwent liver transplantation. Int. J. Med. Sci. 2007; 4 (2): 105 – 109.
31. Botto S., Bergallo M., Sidoti F., Terlizzi ME, Astegiano S., Ponti R. et al. Detection of PARV4, genotypes 1 and 2, in healthy and pathological clinical specimens. New Microbiol. 2009; 32: 189 – 192.
32. Ekman A., Hokynar K., Kakkola L., Kantola K., Hedman L. et al. Soderlund-Venermo M. Biologikal and immunological relations among Human Parvovirus B19 genotypes 1 to 3. Virol. 2007; 81 (13): 6927 – 6935.
33. Klimovich N.V., Matveev V.A., Romanov O.N., Chernivtsi M.A. Epidemiological characteristics of parvovirus infection in children with hematological diseases. Maternal and child health. 2011; 1: 42 – 46 (in Russian).
34. Brown K.E., Hibbs J.R., Gallinella G., Anderson S.M., Lehman E.D., McCarthy P. Resistance to Parvovirus B19 infection due to lack of virusreceptor (erythrocyte P antigen). N. Engl. J. Med. 1994; 330 (17): 1192 – 1196.
35. Weigel-Kelley K.A., Yoder M.C., Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transductionof human hematopoietic cells. J. Virol. 2001; 75 (9): 4110 – 4116.
36. Jordan J.A., DELoia J.A. Globoside expression within the human placenta. Placenta. 1999; 20: 103 – 108.
37. Riipinen A., Vaisanen E., Nuutila M., Sallmen V. et al. Parvovirus B19 infection in fetal deaths. CID. 2008; (47): 1519 – 1525.
38. Riipinen A. Parvovirus B19 infection in fetal deaths. CID. 2008; (47): 1519 – 1525.
39. Schwarz T.F., Nerlich A., Hillemanns R. Detection of parvovirus B19 in fetal autopsies Arch. Gynecol. Obstet.1999; 253 (4): 207 – 213.
40. Wong A. Seroprevalence of Cytomegalovirus, Toxoplasma and parvovirus in pregnancy. Singapore Med. J. 2000; 1 (4): 151 – 155.
41. De Jong E.P. Parvovirus B19 infection in pregnancy. J. Clin. Virol. 2006; 36: 1 – 7.
42. Porter H.J., Quantrill A.M., Fleming K.A. B19 parvovirus infection of myocardial cells. Lancet. 1988; 1: 535 – 536.
43. Young, N.S., Brown K.E. Mechanisms of disease: Parvovirus B19 Engl. J. Med. 2004; 350 (6): 586 – 597.
44. Crane J., Mundle W., Boucoiran I. Matemal Fetal Medicine Committee, Gagnon R., Bujold E., Basso M. Parvovirus B19 infection in pregnancy. J. Obstet. Gyneacol. Can. 2014; 36 (12): 1107 – 1116. Available at: http://www. ncbi.nlm.nih.gov/pubmed/25668048; http://sogc.org/wp-content/ uploads/2014/12/ gui3161012E.pdf.
45. Anderson L.J., Tsou C., Parker R.A,. Chorba T.L., Wulff H., Tattersal P. . Detection of antibodies and antigens of human parvovirus B19 by enzume-linked immunosorbent assay. J. Clin. Microbiol. 1986; 24: 522 – 526.
46. Heegaard E.D., Brown K.E. Human parvovirus B19. Clinical microbiology reviews. 2002; 15 (3): 485 – 505.
47. Antipovа A.Y. The value of laboratory diagnosis of rubella and parvovirus infection in the elimination of rubella:.Doctorate of biol. sci. diss. St. Petersburg; 2013. 23 (in Russian).
48. Diagnosis of infections caused by parvovirus B.Available at http://www.cirlab.ru/library/73/4554.
49. Giorgio E., De Oronzo M.A., Iozza I., Di Natale A., Cianci S., Garofalo G. et al. Parvovirus B19 during pregnancy. J. оf Prenatal Medicicne. 2010; 4 (4): 63 – 66.
50. Fairley C.K., Smoleniec J.S., Caul O.E., Miller E. Observational study of effect of intrauterine transfusion on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346: 1335.
51. Mossong, J. et al. Parvovirus B19 infection in the European countries: seroepidemiology, force of infection, and maternal risk of infection. Epidemiol. Infect. 2008; 136 (8): 1059 – 1068.
52. Gillespie S.M., Cartter M.L., Asch S., Rokos J.B., Tsou C. J., Gary G. Occupational risk of human parvovirus B19 infection forschool and day-care personnel during an outbreak of erythema infectiosum. J. Am. Med. Assoc. 1990; 263 (15): 2061 – 2065.
53. Enders M. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany M. Enders, A. Weidner, G. Enders. Epidemiol. Infect. 2007; 135: 563 – 569.
54. Medvedeva V.V.,Skorodumova N.P., Kucherenko N.P., Goncharova L.A., Kovalenko T.I., Legkaya V.A. et al. Clinical and epidemiological features of parvovirus infection detection in Donetsk region. Medical-social problems of the family. 2013; 2 (18): 98 – 101 (in Russian).
55. Filatova E.V., Novikova N.A., Zubkov N.V., Golitsyn L.N., Kuznetsov K.V. Determination of markers in samples of the parvovirus B19 blood donor. Journal of Epidemiology and Microbiology, Immunology. 2010; 5: 67 – 70 (in Russian).
56. Elizhbaeva M.A. Parvovirus B19 in blood donors and patients with hematological hospital. Doctorate of med. sci. diss. Moscow;2011 (in Russian).
57. Candotti D., Etiz N., Parsyan A. et al. Indentification and sharacterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 2004; 78: 12169 – 12178.
58. Candotti D., Etiz N., Parsyan A. et al. Indentification and sharacterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 2004; 78: 12169 – 12178.
59. Parvovirus infection. Available at: http: // www.pitermed.com / simptomy-bolezni /? Cat = 6 & word = 54191 (03.03.2015.).
Review
For citations:
Nikishov O.N., Kuzin A.A., Antipova A.Yu., Lavrent’eva I.N. Parvovirus Infection – Contemporary Issues in Epidemiology and Clinical Medicine. Epidemiology and Vaccinal Prevention. 2015;14(4):29-35. (In Russ.) https://doi.org/10.31631/2073-3046-2015-14-4-29-35
Views:
1454
Email this article 